|
KMID : 0360319930250030334
|
|
Journal of Korean Cancer Research Association
1993 Volume.25 No. 3 p.334 ~ p.342
|
|
|
Usefulness of CA72-4 in Gastric Carcinoma and Other Gastrointestinal Malignancies
|
|
안명주
홍진선/황일란/김상위/서철원/이규형/이정신/김명환/민영일
|
|
|
Abstract
|
|
|
Background:
Gastric cancer is one of the most frequent cancers in Korea, but none of many available tumor markers has made an early diagnosis or monitoring of the development of gastric cancer possible.
The serum levels of CA72-4 as a new tumor marker were measured by a radioimmunometric assay for evaluating of its clinical significance as a possible tumor marker, especially in gastric cancer.
Patients and Methods:
The CA72-4 serum levels were measured in health control (n=39) and patients with benign (n=50) or malignant gastrointestinal diseases (n=241) containing gastric carcinoma (n=155) using novel quantitative immunoradiometric assay. A cut of 6U/ml
was
used.
@ES Results:
@EN 1) The median value of CA72-4 in gastric cancer was not different from that of the benign gastrointestinal disease or control group.
2) The specificity of CA72-4 was 92% in benign gastrointestinal disease.
3) The sensitivity of CA72-4 in gastric cancer was 38.1% and was not different from that of CEA(34.1%).
4) The sensitivity of CA72-4 was inferior to CA19-9 in pancreatic cancer(61.9% versus 85.7%), biliary cancer(36.4% versus 86.3%, P<0.05) and inferior to CEA in colorectal cancer(48.0% versus 72.0%).
5) The positive rates of CA72-4 were higher in advanced gastric cancer(0% in stageⅠ, 11% in stageⅡ, 25% in stageⅢ, 51.2% in stage IV).
6) Elevated serum levels of CA72-4 in gastric cancer patients preoperatively decreased to below the cut off value after radical gastric surgery.
7) The serial CA72-4 levels of 9 unresectable gastric cancer patients who received palliative chemotherapy correlated roughly with tumor response.
8) There was no significant correlation between CA72-4 and CEA in gastric cancer.
Conclusion:
Our data indicates that CA72-4 had relatively low sensitivity for gastric cancer(38.1%) and should not be used as a screening test, but should permit the monitoring of follow-up and the monitoring of follow-up and the early detection of
recurrences and
therapeutic response.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|